MERÍSTEM

2022FY Off to a Rocky Start

NEIMETH Records Lowest Revenue in 20 Quarters

In its first-quarter scorecard (FY ends in September), **NEIMETH**'s topline performance was unimpressive as it declined by 51.31% YoY to NGN192.11mn (from NGN394.56mn in Q1:2021). This topline performance rested solely on its pharmaceutical segment in the quarter as the animal health segment recorded zero revenue. Although the management has made no divestment announcement concerning the animal health segment, we note that no revenue has been recorded from the segment since Q3:2021 (April- June 2021). Given the firm's impressive performance in its 2020 and 2021 financial periods, the turnout in Q1:2022 was significantly less than expected. The decline in revenue from the pharmaceutical unit is reflective of the intense competition in the industry. The performance in Q1:2022 and absence of revenue from the animal health segment dampens our FY revenue expectations. However, the firm typically records higher revenue in the second half of the year. Therefore, anticipate a moderate topline decline of -1.80% to NGN3.01bn in 2022FY.

Cost to Sales Significantly Above Historical Levels

The firm's production costs declined by 39.90%YoY to NGN178.23mn, closely mirroring the decline in revenue in the quarter. However, cost to sales increased significantly to 92.77%, more than double its six-year average of 43.37%, and higher than its Q1:2021 level of 75.17%. The reduction in total production expenses was mainly anchored by lower material (-78.78%) as it made up the lion share (c.45%). This also signaled a reduction in procurement of raw materials for production. Operating expenses were however up by 25.77% widening the operating losses by 106.88% to NGN295.84mn (from NGN143.14mn). Operating loss margin thereafter widened significantly to -153.99% in Q1:2022 (vs -36.28% in Q1:2021). We anticipate a moderate decline in production costs during the year premised on our expectation of modest topline decrease.

Increase in Short-term Debt Impacts Liquidity Ratios


NEIMETH obtained the second tranche of its NGN2.4bn debt obligation from the Central Bank of Nigeria during the quarter (of NGN400.00MN) which is to be utilized in augmenting working capital. Despite this, its total debt obligations (both short- and long-term debt) reduced slightly by 2.43% due to repayment of previously existing debt obligations. Finance costs thereafter declined by 22.29% to NGN13.27mn. Liquidity ratios- Current and acid test ratio however slowed to 1.98x and 1.33 (from 2.53x and 1.77x in 2021FY) following the increase in the firm's short-term debt by 40.67% to NGN1.49bn (vs. NGN1.06bn in 2021FY). Overall, the firm ended the quarter in a loss position which increased to NGN309.11mn (from NGN178.80mn in Q1:2021). While we expect 2022FY's earnings to turn around and end on a positive note (NGN240.35mn), we view the loss in Q1 as a significant downside which will result in lower net margin of 7.98% in 2022FY (vs. 11.04% recorded in 2021FY).

Recommendation

We revise our target price to NGN2.19 using a target Price to Book Value ratio of 2.55x and an expected book value of NGN0.86. This represents a 20.29% upside based on the closing price on the 2nd of March 2022. Hence, we rate the ticket "**BUY**".

Company	NEIMETH
/aluation (Trailling)	
Trailing EPS	0.11
BVPS	0.58
P/E	16.8x
P/BV	3.1x
Target P/BVPS	2.55x
Dec-2022 Exp. BVPS	0.86
Dec 2022 Target price	2,19
Current Price	1.82
Up/Downside Potential	+20.29%
Ratings	BUY
Key metrics	
ROE	16.37%
ROA	3.29%
Net margin	-160.90%
Asset Turnover	0.45
Leverage	4.97
Yr Hi	1.98
Yr Lo	1.76
YTD return	+3.43%
Beta	1.13
Adjusted Beta	1.08
Shares outstanding	1.90bn
Market cap [NGN]	3.46bn
Financial year end	Sep
Most Recent Period (MRP)	Q1:2022

March 02, 2022



-NGXASI -

- NEIMETH

NSE: NEIMETH I Bloomberg: NEIMETH:NL I Reuters: NEIMETH.LG

MERÍSTEM

March 02, 2022

Chart 1: Sensitivity Analysis

Sensitivity Analysis of Dec-2022 Target Price to key model inputs						Min	1.63	
			B/V					2.82
		0.80	0.83	0.86	0.89	0.93		
	2.0x	1.63	1.69	1.76	1.83	1.90	-	
Taurant D/D)/	2.3x	1.83	1.90	1.97	2.05	2.13		
Target P/BV	2.5x	2.03	2.11	2.19	2.27	2.36		
	2.8x	2.23	2.31	2.40	2.50	2.59		
	3.0x	2.42	2.52	2.62	2.72	2.82	_	

Financial Highlights and Forecasts (NGN billion)							
Profit & Loss Account	Q1:2021A	Q1:2022A	2022F	2023F	2024F	2025F	2026F
Revenue	0.39	0.19	3.01	3.30	3.68	4.18	4.82
Cost of sales	0.30	0.18	1.35	1.54	1.72	1.95	2.27
Gross profit	0.10	0.01	1.66	1.76	1.96	2.23	2.55
Operating expense	0.24	0.31	1.03	1.15	1.21	1.40	1.63
Operating profit	-0.14	-0.30	0.46	0.42	0.53	0.60	0.67
Finance cost	-0.04	-0.01	0.10	0.11	0.11	0.03	(0.07)
РВТ	-0.18	-0.31	0.35	0.31	0.42	0.57	0.60
РАТ	-0.18	-0.31	0.24	0.21	0.29	0.39	0.41
Balance Sheet	2021AA	Q1:2022A	2022F	2023F	2024F	2025F	2026F
Property, Plant and Equipment	1.41	1.45	1.55	1.72	1.94	2.11	2.28
Total Debt	3.81	4.20	3.49	2.13	1.59	0.46	(1.06)
Total Assets	6.33	6.25	5.97	4.75	4.48	3.76	2.31
Total Equity	1.41	1.10	1.59	1.66	1.79	2.02	2.25
Total Current Liabilities	1.93	2.41	1.80	1.65	1.50	1.38	2.10
Non-Current Liabilities	2.92	2.74	2.58	1.44	1.19	0.36	0.77
Total Liabilities	4.85	5.15	4.39	3.09	2.69	1.74	2.87
Financial Ratios	2020A	H1:2021A	2021F	2022F	2023F	2024F	2025F
Gross Margin	24.83%	7.23%	55.20%	53.37%	53.32%	53.36%	52.96%
Operating Margin	-36.28%	-153.99%	15.20%	12.60%	14.53%	14.43%	13.94%
Net Margin	-45.32%	-160.90%	7.98%	6.37%	7.79%	9.29%	8.48%
Return on Asset	-2.81%	-4.93%	4.02%	3.92%	6.21%	9.42%	13.48%
Return on Equity	-13.30%	-24.54%	15.14%	12.97%	16.65%	20.39%	19.15%
Asset Turnover	1.08	0.45	0.50	0.62	0.80	1.01	1.59
Financial Leverage	4.73	4.97	3.76	3.31	2.68	2.16	1.42
Current Ratio	2.50	1.98	2.43	1.81	1.67	1.17	1.17
Quick Ratio	1.74	1.33	1.81	1.10	0.76	0.00	(0.89)

(Q1- First-Quarter); (H1- First-Half); (H2- Second Half) (FY- Full Year) (F- Forecast)



March 02, 2022

Contact Information

	Brokerage and Retail Services topeoludimu@meristemng.com	(+234 905 569	0627)
	isaaconaolapo@meristemng.com	(+234 803 234)	-
	contact@meristemng.com	(,
	Investment Banking/Corporate	Finance	
	rasakisalawu@meristemng.com	(+234 806 022	9889)
	seunlijofi@meristemng.com	(+234 808 536	5766)
	Wealth Management		
	funmilolaadekola-daramola@meristemng.com	(+234 805 498	4522)
	crmwealth@meristemng.com		
	Tel : +234 01 738 9948		
	Registrars		
	muboolasoko@meristemregistrars.com	(+234 803 324	7996)
	martinaosague@meristemregistrars.com	(+234 802 303	1783)
	www.meristemregistrars.com		
	Tel: +23401-280 9250		
	Trust Services		
	damilolahassan@meristemng.com	(+234 803 613	9123)
	trustees@meristemng.com		
	Group Business Development		
	saheedbashir@mersitemng.com	(+234 802 454	6575)
	ifeomaogalue@meristemng.com	(+234 802 3942	2967)
	info@meristemng.com		
	Client Services		
	adefemitaiwo@meristemng.com	(+234 803 694	3034)
	blessingogwuche@meristemng.com	(+234 706 896	5173)
	car@meristemng.com		
	Investment Research		
	timchanggwatau@meristemng.com	(+234 7	703 188 3322)
	research@meristemng.com		
	www.meristemng.com www.meriste	mwealth.com	www.meristemregistrars.com
orporate websites:			
•			
eristem Research ca	in also be accessed on the following platforms:		
	al: meristem.com.ng/rhub		

ISI Emerging Markets: www.securities.com/ch.html?pc=NG

Reuters: www.thomsonreuters.com FactSet: www.factset.com

merístem

Analyst's Certification and Disclaimer

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

(1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and

(2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.

(3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

Investment Ratings

Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

Target Price Estimate

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

Ratings Specification

- **BUY:** Target Price of the stock is above the current market price by at least 10 percent
- HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.
- **SELL**: Target Price of the stock is more than **10 percent** below the current market price.



Nigeria | Equities | NEIMETH | Q1:2022

Definitions

Price Targets: Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

Asset allocation: The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

Movements in Price Target

Company Name: FIDSON Healthcare Plc

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
03-Mar-2021	1.82	-	2.19	-	BUY

Company disclosures

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

Company	Disclosure
NEIMETH International Pharmaceuticals Plc	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.

Conflict of Interest

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

Nigeria | Equities | NEIMETH | Q1:2022



March 02, 2022

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

Important Disclosure

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Mersitem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2022 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited.